New activity is brewing for Alcon ( (CH:ALC) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
On August 5, 2025, Alcon announced a definitive merger agreement to acquire STAAR Surgical Company, a leader in refractive surgery using Implantable Collamer Lenses (ICLs). This acquisition, valued at approximately $1.5 billion, aims to enhance Alcon’s laser vision correction business and provide a comprehensive range of myopia treatment options. The transaction, which offers a significant premium to STAAR’s stock price, is expected to be accretive to Alcon’s earnings in the second year and is anticipated to close within six to 12 months, subject to customary conditions. This strategic move positions Alcon to address the growing global demand for myopia solutions, leveraging STAAR’s innovative EVO ICL technology.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF84.30 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon is a global leader in eye care, dedicated to helping people see brilliantly. With a heritage spanning over 75 years, Alcon offers a broad portfolio of products to enhance sight and improve people’s lives, focusing on Surgical and Vision Care products.
Average Trading Volume: 990,065
Technical Sentiment Signal: Sell
Current Market Cap: CHF35.89B
Find detailed analytics on ALC stock on TipRanks’ Stock Analysis page.